Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Leiner & loratadine

This article was originally published in The Tan Sheet

Executive Summary

Company's "goal is to create marketing programs to enable [its loratadine] retail private label sales to exceed 30% of the market," which it anticipates "to be $500 mil.," firm says. Leiner expects to ship its generic version of Schering-Plough's OTC Claritin in mid-July (1"The Tan Sheet" Feb. 10, 2002, p. 8). Company notes it will support initial loratadine offering by conducting "in-store promotions and regional advertising in conjunction with [its] retail consumers." Leiner will consider manufacturing, marketing other forms of loratadine at a later date, firm adds, noting that, overall, it expects "to introduce into the market new innovative products...that will generate $100 mil. in gross sales" in 2003...

You may also be interested in...

Leiner Store Brand Loratadine To Begin Retail Shipments In July

Leiner Health Products plans to begin shipping private label OTC loratadine immediate-release 10 mg tablets "on or around" July 21, according to the firm

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts